Austin, TX, July 23, 2015 --(PR.com
)-- NanoHybrids Inc, a biotechnology company based in Austin, Texas, and Eikonix, UK, a distributor of imaging systems and contrast agents announced today that they have entered into an agreement that adds NanoHybrids’ premium gold nanoparticles to Eikonix's extensive offering of scientific research products and services.
NanoHybrids’ initial technology platform was developed in collaboration with researchers from the Biomedical Engineering Department at The University of Texas at Austin and M.D. Anderson Cancer Center. In addition to gold nanoparticles with regular coatings such as citrate, CTAB and PEG, the company’s products include an exclusive line of silica-coated gold nanoparticles.
NanoHybrids offers several advantages over its competitors:
Monodisperse gold nanoparticles with well-defined, narrow LSPR peaks
Low batch-to-batch variability to ensure consistent results.
Full transparency on surface chemistry
Compared to currently available preclinical imaging contrast agents on the market, NanoHybrids’ silica-coated nanorods and spheres provide several benefits including high colloidal and thermodynamic stability, enhanced signal strength, and bioconjugation potential, making them an excellent choice for in vitro and in vivo imaging.
NanoHybrids gold nanoparticles are excellent for providing contrast in a wide variety of biological applications and optical imaging techniques including photoacoustic imaging, optical coherence tomography, microscopy, SERS and lateral flow assays.
“Since our launch last year, NanoHybrids products have been quickly gaining popularity with imaging researchers thanks to our high quality and personalized customer service,” said Nishi Viswanathan, Director, Product Development & Marketing at NanoHybrids. “We are very pleased to partner with Eikonix, and believe that this agreement will reinforce NanoHybrids’ position as a worldwide supplier of high quality gold nanoparticles and contrast agents. With its strong team and tight focus on scientific and healthcare markets, Eikonix will help promote the benefits of our technology to researchers in the imaging industry.”
“The addition of NanoHybrids’ gold nanoparticles further strengthens our commitment to provide specialized support for imaging applications,” said Paul Elwood, CEO of Eikonix."The superior features of NanoHybrids’ gold nanoparticles make them highly attractive for use in imaging related applications where quality, sensitivity and consistent results are key. This agreement will provide us with a product to more effectively address this fast growing market."
Eikonix offers an unrivaled choice of systems for those working in the fields of gel imaging, colony counting and zone measuring, fluorescence imaging and live cell counting and imaging. These products offer a significant technical or price advantage over the competition. The company is dedicated to serving the scientific and healthcare markets with an extensive range of innovative, technological products supported by highly skilled and knowledgeable people who put the customer first.
NanoHybrids is an Austin-based company focused on commercializing nanotechnology solutions that can enhance the non-invasive detection and molecular profiling of cancer, atherosclerosis and other diseases. The company’s current product line comprises of premium gold nanoparticles with specialized coatings, including citrate, CTAB, PEG and a proprietary silica coating that provides colloidal stability, bioconjugation potential and enhanced optical properties. The nanoparticles are ideal for use in imaging, tumor targeting, microscopy, lateral flow assays, SERS, drug delivery research, sensors and several other high-technology applications within the fields of life science and materials science.